Ceci est une version HTML d'une pièce jointe de la demande d'accès à l'information 'The Vaccines Procurement Steering Committee & the Joint Negotiation Team'.

From:
To:
 (SG); 
@aemps.es
Cc:
Subject:
[Confidential] RE: TC Moderna / Joint Negotiation Team EU 
Date:
lundi 29 juin 2020 05:11:38
Attachments:
CONFIDENTIAL - Moderna - Advance Purchase and Supply Agreement - 06.28.20 (shared).DOCX
Dear 
Thank you for the time this weekend to connect over our proposal to the European Commission. We
appreciate the insightful questions and are looking forward to continuing our dialog.
As promised, please find attached the framework I summarized on the call: an Advance Purchase
and Supply Agreement where the key supply terms for the Member State Supply Agreement are
captured in Exhibit B. I trust you would treat this document with utmost confidentiality.
We have time blocked for 8am ET (14:00 CET). Please let us know if you intend to include your legal
counsel on the call. Appreciate your guidance.
Separately, 
 please let us know if you are having any issues with accessing the dataroom.
Best regards,
From: 
Sent: Saturday, June 27, 2020 7:23 PM
To: 
@regeringskansliet.se>
Cc: 
@aemps.es; 
@ec.europa.eu; 
@modernatx.com>; 
@modernatx.com>; 
@modernatx.com>
Subject: Re: TC Moderna / Joint Negotiation Team EU 
Well said 
We are united around a common purpose to help the world get out of this crisis. 
I am copying two of my colleagues,
 asking them to please set up the WebEx call. 
Looking forward to speak to you tomorrow. 
Regards 
Sent from my iPhone
On Jun 27, 2020, at 7:19 PM, 
@regeringskansliet.se> wrote:
We all work 24/7 on this. Incl all the good people in the private sector I know.



@regeringskansliet.se>,
@modernatx.com>
Ämne: Re: TC Moderna / Joint Negotiation Team EU 
 
Dear
I am personally available to assist in moving this along at the right speed.
My mobile number 
Please feel free to give me a call tomorrow, Sunday if I can assist.
Regards
 
 
From: 
aemps.es>
Date: Friday, June 26, 2020 at 5:54 PM
To: 
@modernatx.com>, 
modernatx.com>, 
modernatx.com>, 
modernatx.com>
Cc: 
@ec.europa.eu>,
@gov.se>
Subject: RE: TC Moderna / Joint Negotiation Team EU 
 
Dear team from Moderna,
As the 
 shouldn’t be the centre of our discussion instead of exploring the feasibility of
the advance purchase agreement for the EU, I would suggest to change the focus to a 
 
 Of course, that 
 may include
any clause regarding confidentiality but also other aspects that are as well important for both
parts. My proposal is that you share with us a document outlining the key principles of that
 and to arrange a TC soon after we receive the document to start the
discussions on some concrete grounds.
We hope this is acceptable for you
Best regards,
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
Calle Campezo 1  •  Edificio 8  •  E-28022 Madrid  •  España/Spain
 
CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación
anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no
es el destinatario, le solicitamos que nos lo indique, no comunique su contenido a
terceros y proceda a su destrucción.
CONFIDENTIALITY. The content of this message and any attached information is
confidential and exclusively for the use of the addressee. If you are not the
addressee, we ask you to notify to the sender, do not pass its content and delete the
original.
 
De: 
 

Enviado el: jueves, 25 de junio de 2020 15:00
Para: 
@modernatx.com>;
@ec.europa.eu; 
@aemps.es>
CC: 
@modernatx.com>; 
@modernatx.com>; 
x@xxxxxxxxx.xxx>; 
Asunto: RE: TC Moderna / Joint Negotiation Team EU 
 
 
Dear
,
 
I hope you are both keeping well.
 
Please let me know if a brief call would be helpful to discuss any questions
you may have on the 
, or if there is anything else we can do to help
expedite this.
 
Best regards
 
 
 
From: 
@modernatx.com> 
Sent: 24 June 2020 19:56
To
@ec.europa.eu; 
@aemps.es
Cc: 
@modernatx.com>; 
@modernatx.com>;
@modernatx.com>;
Subject: RE: TC Moderna / Joint Negotiation Team EU
 
Dear 
,
 
Thank you for your update and clarification around confidentiality.
 
To facilitate the process, we have attached a proposal for a simple
confidentiality agreement which could be entered between Moderna and the
EC. This agreement would cover related parties which the EC would need to
share information with as “Representatives” e.g. representatives of member
states. This would enable us to only enter into one agreement and enable
information sharing on your side to enable your process.



broadly speaking, the Commission has a certain amount of funds at its
immediate disposal which may be used to cover e.g. down-payments.
However it does not have the funds to pay for the full amount of vaccines
– this will be done by Member States under the terms of the Advance
Purchase Agreement agreed by the Commission. The actual purchase
contracts will be concluded between each country and the company
concerned on the basis of the APA
 
As regards allocation of doses, the Commission and the Member States
will arrange this amongst themselves.
 
Further information on all of this can be found in the EU’s strategy on
COVID-19 vaccines, adopted last week:
https://ec.europa.eu/info/files/communication-eu-strategy-covid-19-
vaccines_en 
 
As regards confidentiality, every member of the Steering Board has signed
a conflict of  interest and confidentiality declaration. Commission staff are
covered by a legal obligation of confidentiality, as per Article 17 of the EU
Staff Regulations: https://eur-lex.europa.eu/legal-content/EN/TXT/?
uri=CELEX%3A01962R0031-20140501
 
I hope that this provides you with clarity and reassurance on these point
 
Regards,
 
 
 
SG Unit D3 (Employment, Education, Social Affairs, and Health)
 
<image007.png>
 
 
 
From: 
@modernatx.com> 
Sent: Tuesday, June 23, 2020 7:12 PM
To:
@aemps.es; 
 (SG)
Cc: 
@modernatx.com>; 
@modernatx.com>;
@modernatx.com>
Subject: Re: TC Moderna / Joint Negotiation Team EU
 
Dear 
Thank you very much for the productive call this morning. We
 sincerely appreciate you clarifying the process for how the supply

of vaccines to protect populations across the EU, will proceed.
 
Can you please provide further clarity on a few points:
-          Will the EU Commission be using an “umbrella
agreement” approach i.e. negotiating and agreeing to a
demand and supply agreement for the entire EU?
-          If yes, does it mean that the EU Commission will place an
order for a certain number of doses for the entire EU and
then allocate doses to the member states?
-          Can you please provide any further clarity on how
allocation of doses will be handled? 
 
As we mentioned on the call, Moderna welcomes the opportunity
to work with all of you to secure early access to MRNA 1273, a
vaccine that we believe has the potential to play an important
role as part of the arsenal that the EU Commission and countries
can deploy, to protect vulnerable populations at risk.
 
Looking forward to continuing the dialogue.
 
Regrds
 
From: 
@aemps.es>
Date: Tuesday, June 23, 2020 at 8:33 AM
To: 
ec.europa.eu>,
@modernatx.com>, 
@modernatx.com>,
modernatx.com>, 
@modernatx.com>
Subject: TC Moderna / Joint Negotiation Team EU
 
Thank you for the fruitful discussion,
Copied in this mail you have all the attendees to the meeting
We look forward to continue
Best regards,
 
Agencia Española de Medicamentos y Productos Sanitarios
(AEMPS)
Calle Campezo 1  •  Edificio 8  •  E-28022 Madrid  •  España/Spain
 
CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier
documentación anexa es confidencial y va dirigido únicamente al
destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos
lo indique, no comunique su contenido a terceros y proceda a su

destrucción.
CONFIDENTIALITY. The content of this message and any attached
information is confidential and exclusively for the use of the addressee. If
you are not the addressee, we ask you to notify to the sender, do not pass
its content and delete the original.
 
CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier
documentación anexa es confidencial y va dirigido únicamente al
destinatario del mismo. Si Usted no es el destinatario, le solicitamos que nos
lo indique, no comunique su contenido a terceros y proceda a su destrucción.
CONFIDENTIALITY. The content of this message and any attached
information is confidential and exclusively for the use of the addresser. If
you are not the addresser, we ask you to notify to the sender, do not pass its
content and delete the original.
Please consider the environment before printing
this email
Confidentiality notice and disclaimer: The information in this message and
any attachments is intended for the exclusive use of the addressee(s), is
confidential and may be privileged or otherwise protected from disclosure.
Any review, retransmission, dissemination or other use of, or taking of any
action in reliance upon, of any such information by persons or entities other
than the intended addressee(s) is prohibited. If you have received this
message in error and are not the intended addressee, please notify the sender
immediately and delete this message and any attachments from your system
without reading or disclosing them. If you are not the intended addressee, be
advised that any use of the information in this message and any attachment
is prohibited and may be unlawful, and you must not copy this message or
attachment or disclose the contents to any other person.
*******************************************************************
This message was sent from Goodwin Procter LLP and is intended
only for the designated recipient(s). It may contain confidential or
proprietary information and may be subject to the attorney-client
privilege or other confidentiality protections. If you are not a
designated recipient, you may not review, copy or distribute this
message. If you receive this in error, please notify the sender by reply
e-mail and delete this message. Thank you.
*******************************************************************
CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier
documentación anexa es confidencial y va dirigido únicamente al destinatario del
mismo. Si Usted no es el destinatario, le solicitamos que nos lo indique, no
comunique su contenido a terceros y proceda a su destrucción.
CONFIDENTIALITY. The content of this message and any attached information is
confidential and exclusively for the use of the addresser. If you are not the addresser,
we ask you to notify to the sender, do not pass its content and delete the original.